(Q45858306)

17 December 2017

title

Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor (English)

1 reference

17 December 2017

author name string

Ade Kallas

1

1 reference

17 December 2017

Margus Pooga

2

1 reference

17 December 2017

Abdellah Benhida

3

1 reference

17 December 2017

Marc Jacquemin

4

1 reference

17 December 2017

Jean-Marie Saint-Remy

5

1 reference

17 December 2017

language of work or name

1 reference

1 September 2002

1 reference

17 December 2017

published in

Thrombosis Research

1 reference

17 December 2017

volume

107

1 reference

17 December 2017

issue

6

1 reference

17 December 2017

page(s)

291-302

1 reference

17 December 2017

cites work

Factor VIII inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Immune tolerance and the immune modulation protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

The A1 and A2 subunits of factor VIIIa synergistically stimulate factor IXa catalytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Identification of novel factor VIII inhibitor epitopes using synthetic peptide arrays

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Localization of a factor X interactive site in the A1 subunit of factor VIIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Role of factor VIII C2 domain in factor VIII binding to factor Xa

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

Epitope specificity and functional characterization of factor VIII inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900352-3

7 January 2021

10.1016/S0049-3848(02)00352-3

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017